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“Les han de traer ejemplos palpables, fáciles, inteligibles, demostrativos, 
indubitables, con demostraciones matemáticas que no se pueden negar”
(El Ingenioso Hidalgo Don Quijote de la Mancha, 1, XXXIII)
(Translation: They need examples that are tangible, easy, understandable, 
illustrative, indubitable, and with mathematical proofs that cannot be denied).
Cervantes understood that models–be they physical or moral lessons–are valid only in as 
much as they mirror that which they seek to mimic. This is the essential issue presented by 
Diego et al.1 in the article published in Revista Española de Cardiología. Drug-eluting 
stents have changed the practice of medicine and are perhaps the most common intervention 
used today. Millions of stents are placed each year and yet critical questions remain as to 
whether one design is better than another. The challenge in major part is that, though device 
designs may be significantly different one from another, detection of a clinical difference is 
difficult given the rarity of side effects. Human clinical trials are too small and too short to 
detect differences even in fatal events that occur in 1 in 100 patients per year. The natural 
fallback is to rely on animal model systems and yet it is unclear how best to use them. Diego 
et al.1 describe a study that compares the proliferative response elicited after deployment of 
paclitaxel-eluting and bare metal stents in porcine coronary arteries. They suggest that the 
ability of a stent platform to significantly impact late vascular healing depends upon the 
degree of injury that is created at the time of implantation. Such a result has profound impact 
on how we consider animal model systems for critical technologies, our view of vascular 
biology and vascular repair, and our appreciation of the history of work in this field. 
Moreover, the study shows how a difficult parameter rarely controlled in human 
interventions–the extent of injury–is such a powerful regulator of clinical effect and 
restenotic side effect.
*Corresponding author: Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 
Massachusetts Avenue, E25-438, Cambridge, MA 02139, United States. merche@MIT.EDU (M. Balcells). 
CONFLICTS OF INTEREST
None declared.
HHS Public Access
Author manuscript
Rev Esp Cardiol (Engl Ed). Author manuscript; available in PMC 2016 January 13.
Published in final edited form as:
Rev Esp Cardiol (Engl Ed). 2011 September ; 64(9): 739–742. doi:10.1016/j.rec.2011.05.014.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Angioplasty came to clinical fruition in 1979 with the pioneering work of Gruntzig et al.2 
and endovascular stenting in the late 1980s as the result of equally heroic efforts by Palmaz 
et al.3 and Gianturco el al.4 In a fascinating way clinical impact was realized early but 
required development of precise preclinical model systems5–8 before full clinical potential 
could be realized, and detailed aspects of safety required more complete understanding of 
the basic biology. It is the latter which is the most recent addition to the biology of stents 
and the elements of stent biology that rely most on historical contributions. Indeed, Santiago 
Ramón y Cajal early in his career proposed what was then a controversial issue: the origin of 
inflammation and the migration of leukocytes, and worked later in understanding the 
morphology and anatomy of endothelial cells and their interaction with leukocytes.9 Yet, it 
took almost 75 years for the role of inflammation in vascular disease to come front and 
center–in major part because it was difficult to measure inflammation in man and there were 
few accurate animal models of inflammation and vascular disease. In 1908 Ignatowski10 
produced the first animal model of atherosclerotic disease by feeding rabbits a special diet 
rich in meat, milk, and eggs. Many models followed and in the late 1970s Vesselinovitch11 
listed an extensive wish list of the desirable features of animal models of atherosclerosis: 
“must be easily available and inexpensive […], develop typical lesions with relative ease in 
a practical length of time, […], have some similarity to human anatomy, physiology, and 
biochemistry including serum lipoprotein and lipid metabolism similar to humans, […], and 
demonstrating clinical complications of lesion rupture similar to those seen in humans.” The 
search for appropriate animal models to understand and treat coronary artery disease has led 
to high-fat diet feeding, alone or in combination with physical, chemical, and/or 
immunologic injury to the endothelium. There always seem to be some characteristics of the 
induced disease in these animal models that diverge from the naturally occurring disease in 
human patients and some kind of compromise needs always to be made when selecting an 
animal model. The objective is to establish the best possible match between the model and 
the specific hypothesis being tested.
With the birth of interventional cardiology and the massive adoption of stents for the 
treatment of atherosclerotic vascular disease, proliferative processes like intimal hyperplasia 
lead to restenosis, a clinically relevant event as profound as the obstructive atheromatous 
plaque itself. The deployment of a balloon within a semi-occluded artery reopens the artery 
but is accompanied by extensive recoil, endothelial cell denudation, tissue ingrowth and 
vessel remodeling. Stents significantly reduce recoil, and local drug elution virtually 
eliminates tissue overgrowth, but the device and its drug may exacerbate endothelial damage 
and subsequent thrombosis. What then is the correct model to use and the parameters to 
consider for the complex multilaminate structures that are vessels and whose disease 
involves architectural disruption through endothelial denudation, leukocyte adhesion, 
transmigration and transformation, lipid insudation, and local destruction? What aspects of 
vascular repair are then most important and perhaps best predictors of human safety? When 
and where do we look in animal model systems?
Diego et al.1 extended the questions even further by showing that late impact is heavily 
influenced by initial conditions. They showed that the degree of injury provoked by the 
device deployment dictates the proliferative response and the vascular response to specific 
Balcells and Edelman Page 2
Rev Esp Cardiol (Engl Ed). Author manuscript; available in PMC 2016 January 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
stent platforms. In light of their findings, they pose a very interesting question “Are current 
experimental models valid for drug-eluting stents analysis?” Animal models have been 
indeed very useful in elucidating the pathobiology and complex processes of atherosclerosis 
as well as to assess toxicity of a device, but their use to predict efficacy of stents remains 
limited. We ought to step back and look at the problem from different angles, going back to 
Ramon y Cajal’s early definitions of endothelial cells and inflammatory cells.
In truth there is likely no animal model of any human disease. It is impossible that any 
animal rodent or quadripedal larger species could mimic the processes that beset humans 
late in life. Vascular disease in the animal cannot likely ever fully reflect the cumulative sum 
effects of exposure to environmental factors like tobacco abuse, decades of hypertension, 
abnormalities in lipid and glucose metabolism, and the passing down of specific genetic 
defects. Animal models are invaluable, as is evident here, in addressing circumscribed 
questions where a specific mechanism is at play–does for example, deep vascular injury 
impose a different set of constraints on vascular repair than superficial injury? Here animal 
models are not only appropriate and relevant, but likely the only way to address this issue. 
The spectrum and heterogeneity of human disease cannot allow for such a question to be 
answered in clinical trials. Indeed, the heterogeneity of lesions within the same person 
confounds the premise of a single model use.
The composition and the distribution of cellular and extracellular matrix components of the 
tissue upon vascular intervention and drug-eluting stent implantation evolves with time and 
differs significantly from the original pre-implantation scenario. Recently published data 
demonstrate that disease-induced changes in the distribution of drug-binding proteins and 
interstitial lipid alter the distribution of these drugs,12 forcing one to consider how disease 
might affect the evaluation and efficacy of the local release of these and like compounds 
(Fig. 1). There are therefore not only spectrums of cells within the diseased artery but for 
each cell a range of states the cells can attain. Smooth muscle cells can exist in a synthetic or 
proliferative phenotype, aligned with or separated from their overlying endothelium, packed 
in tight array or dispersed haphazardly within collagen-rich matrix. Inflammatory cells 
similarly play a diverse set of roles. Monocytes are recruited by activated endothelial cells to 
vascular lesions. Stenting enhances these recruiting signals and brings in polymorphonuclear 
cells as well. Each of these cells can promote or retard healing or injury. Monocytes for 
example can exacerbate endothelial injury or promote endothelial cell proliferation13–all 
depending on their state. The endothelium regulates vessel homeostasis in a density-
dependent, flow-dependent, frequency of flow-dependent fashion. Ramón y Cajal knew this 
and we should not be surprised that changes to the structural flatness of healthy endothelial 
cells may be compromised by the disease environment. In short, lesions not only differ from 
species to species and man to man, but within every person–it is no wonder that we cannot 
model such events in an animal.
What then can be done? As above, we can ask good questions and appreciate interesting 
results as Diego el al.1 have done. We can also realize that while no one model can provide 
precise recapitulation of the human experience we can obtain deep insight through the 
integration of results from multiple models. We need not only focus on the biology of 
isolated cells on a cell culture plate or on the results obtained in a particular animal model. 
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Computational models will become even more powerful tools to simulate the fluid mechanic 
environment and to predict drug distribution along the vessel and device outcome in a 
patient/device specific manner.14 We have already seen sophisticated in vitro bioreactors 
that recapitulate not only both the cellular and matrix components but also the mechanic 
environments that blood vessels are exposed to.15 Clinically relevant data can only be 
obtained by interconnecting disciplines to develop new powerful methods. It is increasingly 
evident that critical clinical problems and complex cell-tissue-device interactions may be 
unraveled best by a pandisciplinary approach that brings engineers of all kinds and 
mathematicians together with biologists and physicians (Fig. 2). Only integrated 
approaches–computational, in vitro and in vivo–will enable us to bridge the gap between 
scientific findings and clinical applications. This is perhaps what we should learn from 
Cervantes. First, we need to bring “examples that are tangible, easy, understandable, 
illustrative…” and then support this “…with mathematical validation so that they cannot be 
denied”. It seems like we knew what to do a long time ago.
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Figure 1. 
Local paclitaxel deposition scales associated inversely with lipid content in control (injury + 
normal diet, n = 2) and diseased arteries (injury + cholesterol/oil diet + normal diet, n = 2). 
Fluorescent paclitaxel (green) and lipid (insert, red) distribution in control artery (a) and in 
lesions of varying complexity (b–d). All samples imaged at the same intensity level and 
processed to eliminate backgrounds and artifacts with minimal residual autofluorescence 
exhibited by control arteries that were incubated in phosphate saline.
Reproduced from Tzafriri et al.12 with permission from the publisher. A, adventitia; M, 
media; NI, neointima.
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Figure 2. 
The solution of a clinical problem requires pandisciplinary approaches and communication 
to see the problem as a whole. In parallel, we need to formulate specific questions and 
answer them from different angles applying a variety of methods. Application of such 
approaches will help us to translate clinical symptoms of complex diseases into biological 
targets and therapies that are patient-specific.
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